What is Astrocytoma?
Astrocytomas are one of the most common types of glioma. They arise from astrocytes, which are star-shaped glial cells in the central nervous system.
Astrocytes are the most abundant glial cell type in the brain. They play an important role in maintaining normal brain function by supporting neurons and other glial cells, helping blood vessels supply nutrients to the brain and nervous tissue, and maintaining the blood-brain barrier, which helps restrict harmful substances from entering the brain.
Where is an Astrocytoma located?
Astrocytomas can grow in either the brain or the spinal cord, and the location of the tumour largely determines the symptoms a person may experience. Location varies by age.
Astrocytomas in children
In children and younger patients, astrocytomas commonly arise in the cerebellum. In some cases, they may be located along the midline between the two hemispheres of the brain, where surgery may be more complex or limited because of nearby important brain structures.
Astrocytomas in adults
In adults, astrocytomas are frequently located in the frontal and temporal lobes, but in rarer cases, they may also arise in the brainstem, thalamus, or other regions of the brain.
Table of Contents
| Overview | Excerpt |
|---|---|
Doctors now classify many astrocytomas using both tumour grade and molecular features, particularly whether the tumour has an IDH mutation. | |
Symptoms of astrocytoma vary depending on the tumour’s location, grade, rate of growth, and the age of the patient. | |
MRI is the primary imaging technique. | |
Treatment for astrocytoma is guided by several factors including tumour grade, molecular features, size, location and the patient’s overall health. | |
It is important to know that prognosis is an estimate, not a certainty. | |
Living with, or caring for, a family member diagnosed with astrocytoma can be difficult and emotionally challenging. | |
Research into astrocytoma is advancing rapidly, with clinical trials exploring new ways to treat tumours based on their molecular features. |
Astrocytoma Grades
Grade 1 Astrocytoma – Pilocytic astrocytoma
Pilocytic astrocytoma are slow-growing, circumscribed tumours that arise from astrocytes. They are classified as World Health Organization (WHO) grade 1 gliomas. These tumours usually occur in children and young adults and are among the least aggressive of astrocytomas. Pilocytic astrocytomas can arise anywhere in the central nervous system, but typically develop near the cerebellum and may occur near the brainstem, hypothalamic region, or optic pathway. As these tumours are often well-defined, surgery alone can be effective without the need for further treatment.
Grade 2 Astrocytoma – Astrocytoma IDH-mutant
Grade 2 astrocytoma is a diffuse, infiltrative tumour that arises from astrocytes and typically occurs in adults. Under the WHO 2021 classification, these tumours are usually classified as astrocytoma, IDH-mutant, CNS WHO grade 2. They often do not have well-defined borders because tumour cells can infiltrate surrounding brain tissue. Because of this infiltrative growth, treatment may involve surgery followed by additional therapies in selected cases, depending on factors such as tumour location, symptoms, and molecular features.
Grade 3 Astrocytoma – Astrocytoma IDH-mutant
Grade 3 astrocytoma is a faster-growing, more aggressive form of IDH-mutant astrocytoma with greater cellular activity and infiltration. These tumours are classified as astrocytoma, IDH-mutant, CNS WHO grade 3. The WHO 2021 classification “anaplastic astrocytoma” is an older term and no longer used as a separate entity.
Grade 3 Astrocytoma most often occur in adults and frequently arise in the cerebral hemispheres, although they can develop elsewhere in the central nervous system. Treatment commonly combines surgery with radiotherapy and chemotherapy, depending on individual factors.
Grade 4 Astrocytoma – Astrocytoma IDH-mutant
Grade 4 astrocytoma is the most aggressive form of IDH-mutant astrocytoma and is classified as astrocytoma, IDH-mutant, CNS WHO grade 4. These tumours are infiltrative and fast-growing. It is important to distinguish this diagnosis from glioblastoma, which is defined in modern classification as glioblastoma, IDH-wildtype. Historically, some tumours that are now recognised as grade 4 IDH-mutant astrocytoma were grouped under glioblastoma, but molecular testing now separates these tumour types because they differ in biology and clinical behaviour.
Astrocytoma Progression
It is important to note that a low-grade astrocytoma can acquire additional molecular changes over time and progress to a higher-grade, more aggressive form of glioma. This is one reason why ongoing monitoring and molecular testing can be important in care planning.
Astrocytoma Symptoms
Symptoms of astrocytoma vary depending on the tumour’s location, grade, rate of growth, and the age of the patient. Because the brain controls many essential functions, symptoms often reflect the specific area affected. Faster-growing or more infiltrative tumours may lead to more noticeable neurological changes due to increased pressure within the skull and disruption of normal brain function.
Astrocytoma in children
In children, astrocytomas often arise in the cerebellum, which is located at the back of the brain near the neck.
Tumours in this region may cause symptoms such as:
- Headaches
- Nausea and vomiting, sometimes worse in the morning
- Poor balance and coordination
Astrocytoma in adults
In adults, astrocytomas more commonly develop in the cerebral hemispheres.
Symptoms may include:
- Seizures
- Weakness in the arms or legs
- Speech difficulties
If a tumour develops near structures such as the optic pathway or hypothalamus, symptoms may include:
- Reduced or double vision
- Hormonal or growth-related changes
Symptoms can develop gradually or appear more suddenly, particularly if tumour growth leads to increased intracranial pressure. Any persistent or worsening neurological symptoms should be assessed by a medical professional.
How Is Astrocytoma Diagnosed?
An astrocytoma is typically first suspected based on symptoms and neurological examination, followed by imaging of the brain and spinal cord. Usually, an MRI is the primary imaging technique. MRI images provide detailed information about the location, size and characteristics. If a patient has a pacemaker or certain implants that prevent MRI scanning, a CT scan may be performed instead.
If imaging suggests a tumour, surgery or a biopsy is usually performed to obtain a tissue sample. This sample is examined by a neuropathologist to confirm the diagnosis and determine the tumour type, grade, and molecular features. Molecular testing is now a standard part of diagnosis and helps guide treatment decisions.
Your healthcare team will also carry out a neurological examination and review your medical history at the time of diagnosis to determine the most appropriate treatment approach, with the goal of preserving neurological function and quality of life.
Together, the results from clinical examinations, imaging studies, and tissue analysis are used for establishing a diagnosis and developing an effective treatment plan.
Astrocytoma Treatment and Management Options
Treatment for astrocytoma is guided by several factors, including tumour grade, molecular features such as IDH mutation status, size, location and the patient’s overall health. Care is typically planned by a multidisciplinary team to ensure the most appropriate approach.
Surgery, if it can be performed safely, is often the first step, with the goal of removing as much tumour tissue as possible, while preserving neurological function. For grade 1, well-circumscribed gliomas, surgery alone may be sufficient, although ongoing monitoring is usually recommended as well as additional treatment if deemed necessary.
Diffuse astrocytomas are infiltrative and cannot usually be completely removed with surgery alone. Additional treatment is often considered based on tumour behaviour and molecular characteristics. This may include radiotherapy, chemotherapy, or a combination of both.
Higher-grade astrocytomas are typically treated using a multimodal approach that combines surgery with radiotherapy and chemotherapy. Treatment intensity and sequencing are individualised, particularly for IDH-mutant tumours, which often have a different clinical course compared with glioblastoma (IDH-wildtype).
During follow-up, imaging may sometimes show changes that look like tumour growth. This phenomenon, known as pseudoprogression, usually reflects treatment changes rather than true tumour progression.
If the tumour returns, your healthcare team will carefully consider the best next steps. This decision may depend on factors such as your quality of life, neurological functions, previous treatments, the time to recurrence, and whether participation in a clinical trial is appropriate based on your individual tumour characteristics.
Astrocytoma Survival Rate and Prognosis
The outlook for astrocytoma varies widely and depends on several factors, including tumour grade, molecular features including IDH mutation status, tumour location, age at diagnosis, extent of surgical removal, and overall health.
It is important to know that prognosis is an estimate, not a certainty. Doctors use information such as tumour biology, molecular features, treatment response, and overall health to guide these estimates, but they cannot predict exactly how the tumour will behave. As a result, prognosis is often an ongoing process and may change over time based on how well the tumour responds and how treatment affects you.
In general, lower-grade IDH-mutant astrocytomas are associated with longer survival, and many patients live for years after diagnosis. Higher-grade astrocytomas tend to behave more aggressively and usually require more intensive treatment. However, survival can vary substantially even within the same grade because tumour biology plays a major role.
Living With Astrocytoma
Living with, or caring for, a family member diagnosed with astrocytoma can be difficult and emotionally challenging. Psychological screening and early educational support can help patients and families understand what life may look like before, during, and after treatment. Reporting new or worsening symptoms promptly, such as persistent headaches or new neurological changes, can support prompt medical evaluation and timely treatment.
Psychosocial support and palliative care services may be offered, particularly when the tumour is at an advanced stage and treatment approaches are more intensive to limit tumour spread. Palliative care can be introduced at any stage of illness.
Your healthcare team may also offer genetic counselling for individuals with a strong family history of brain cancer or a known hereditary syndrome to clarify whether genetic factors may be relevant.
Symptoms can often be proactively managed with medications such as pain relief and corticosteroids to reduce inflammation. Early social and supportive interventions may help reduce the risk of complications and improve overall wellbeing.
Rehabilitation therapies such as physical, occupational, and speech therapy may be incorporated to address functional challenges and support independence.
Patients will also often be encouraged to maintain healthy lifestyle habits, including balanced nutrition and appropriate physical activity, and to avoid known risk factors such as unnecessary exposure to ionising radiation.
Research, Clinical Trials, and Hope for the Future
Research into astrocytoma is advancing rapidly, with clinical trials exploring new ways to treat tumours based on their molecular features. Many of these studies focus on therapies designed to target specific genetic changes, improve treatment precision, and reduce long-term side effects.
One promising area of research involves vaccines that target mutations in the IDH gene, which are commonly found in diffuse astrocytomas. Early studies suggest these vaccines can stimulate an immune response against tumour cells and may help delay tumour progression.
Targeted therapies are also being investigated. Drugs that interfere with tumour growth pathways are being studied to determine whether they can slow disease progression while limiting harm to healthy brain tissue.
Cell-based immunotherapies represent another emerging strategy. CAR T-cell therapies, including treatments targeting GD2, are under investigation for aggressive brain tumours such as diffuse midline glioma. While these approaches remain experimental, early-phase trials have shown encouraging signs of activity.
Researchers are also working to refine existing treatments. Some clinical trials are evaluating whether treatment intensity can be safely reduced for patients with more favourable tumour biology, with the goal of preserving cognitive function and quality of life without compromising tumour control.
Although not every experimental therapy will prove effective, each clinical trial contributes to a deeper understanding of brain tumours and helps move the field toward more personalised treatment approaches. Patients may wish to speak with their healthcare team about whether participation in a clinical trial is appropriate for their individual situation.
At Cure Brain Cancer Foundation, we are committed to supporting innovation and funding breakthroughs in neuro-oncology. Explore the research we’re funding to help drive breakthroughs in how we understand and treat brain cancer. You can also learn more about other types of brain cancer to give you the clarity you need.
Astrocytoma FAQs
Is astrocytoma a type of brain cancer?
Yes. Astrocytoma is a type of glioma and belongs to a broader group of central nervous system tumours that can develop in the brain or spinal cord. Gliomas arise from glial cells, which help support nerve cells in the central nervous system. Some rarer astrocytoma-related tumours, such as subependymal giant cell astrocytoma, have different features and may be discussed separately by a person’s medical team.
Can an astrocytoma be completely removed?
Some astrocytomas may be completely removed if tumour resection (surgical resection) can be performed safely. This is more likely when the tumour is well-defined and located away from important brain structures. Diffuse or higher-grade astrocytomas can be harder to remove completely because cancer cells may grow into surrounding normal brain tissue. In these cases, treatment options may include ongoing monitoring, surgery, radiation therapy, chemotherapy, supportive care or clinical trials, depending on the person’s individual diagnosis.
How is astrocytoma different from glioblastoma?
Astrocytoma and glioblastoma are both types of glioma, but they are not always the same diagnosis. Modern classification considers the tumour’s grade and molecular features, including genetic mutations such as IDH status. Grade 4 IDH-mutant astrocytoma is different from glioblastoma, IDH-wildtype. Molecular testing helps separate these tumour types because they can differ in their biology, behaviour and treatment planning.
What should I ask my healthcare team about an astrocytoma diagnosis?
It may be helpful to ask your healthcare team what your magnetic resonance imaging, or MRI, shows about the tumour’s location, size and relationship to nearby brain structures. You may also want to ask about the tumour’s grade, molecular features and what these details may mean for treatment planning. Other useful questions may include which signs and symptoms to monitor, including seizures, headaches, weakness, speech changes, vision changes or cognitive difficulties. You can also ask about possible treatment options, side effects, rehabilitation, supportive care and whether any clinical trials may be relevant.
Disclaimer: : All Cure Brain Cancer Foundation website content is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. You should seek your own medical advice from your doctor or other qualified health professionals.
References
Effinger, K. E., Stratton, K. L., Fisher, P. G., Ness, K. K., Krull, K. R., Oeffinger, K. C., Armstrong, G. T., Robison, L. L., Hudson, M. M., Leisenring, W. M., & Nathan, P. C. (2019, 2019/01/01/). Long-term health and social function in adult survivors of paediatric astrocytoma: A report from the Childhood Cancer Survivor Study. European Journal of Cancer, 106, 171-180. https://doi.org/https://doi.org/10.1016/j.ejca.2018.10.016
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106. PMID: 34185076; PMCID: PMC8328013.
Kessler, T., Ito, J., Wick, W., & Wick, A. (2023, May). Conventional and emerging treatments of astrocytomas and oligodendrogliomas. J Neurooncol, 162(3), 471-478. https://doi.org/10.1007/s11060-022-04216-z
Mackintosh, C., Butterfield, R., Zhang, N., Lorence, J., Zlomanczuk, P., Bendok, B., Zimmerman, R., Swanson, K., Porter, A., & Mrugala, M. (2020, 2020-09-11). Does location matter? Characterisation of the anatomic locations, molecular profiles, and clinical features of gliomas. Neurologia i Neurochirurgia Polska, 54(5), 456-465. https://doi.org/10.5603/PJNNS.a2020.0067
Mount, C.W., Majzner, R.G., Sundaresh, S., et al. (2018) ‘Potent antitumor efficacy of anti-GD2 CAR T cells in diffuse midline glioma’, Nature Medicine, 24, pp. 572–579.
Platten, M., Bunse, L., Wick, A., et al. (2021) ‘A vaccine targeting mutant IDH1 in newly diagnosed glioma’, Nature Medicine, 27, pp. 460–469.
Posti, J. P., Bori, M., Kauko, T., Sankinen, M., Nordberg, J., Rahi, M., Frantzén, J., Vuorinen, V., & Sipilä, J. O. T. (2015, 2015/02/01). Presenting symptoms of glioma in adults. Acta Neurologica Scandinavica, 131(2), 88-93. https://doi.org/https://doi.org/10.1111/ane.12285